Unlocking the potential: Cannabidiol (CBD) as a promising anti-tumor agent.
Cannabidiol (CBD), the primary non-psychoactive component of cannabis, is renowned for its antiepileptic, analgesic, and anti-inflammatory properties. Emerging evidence highlights its potential as an anti-tumor agent, yet significant heterogeneity in preclinical studies and an incomplete mechanistic understanding impede its clinical translation.
This review aims to systematically evaluate the anti-tumor efficacy, underlying mechanisms, and safety profile of CBD, and to discuss the challenges and future directions for its application in oncology.
A systematic review.
We integrated recent high-quality research to assess CBD's effects across various cancer types. The analysis encompassed its mechanisms in tumor cell biology and the tumor microenvironment (TME), a comparison of monotherapy versus combination therapy efficacy, its role in managing cancer-related symptoms, and its pharmacokinetic/pharmacodynamic properties. Advances in nano-based drug delivery systems were also reviewed.
CBD demonstrates multi-target anti-tumor effects, including inhibiting proliferation, inducing apoptosis, suppressing metastasis, and remodeling the TME via immunomodulation. It exhibits broad-spectrum efficacy in vitro and in vivo, shows synergistic effects in combination therapy, and can alleviate cancer-related symptoms. Safety data indicate a favorable tolerability profile. However, current evidence relies predominantly on preclinical models.
CBD holds substantial promise as an anti-tumor agent. This review provides a theoretical foundation for its rational development. Future work should focus on validating these findings in clinical trials, optimizing targeted drug delivery systems, and establishing standardized treatment protocols.
This review aims to systematically evaluate the anti-tumor efficacy, underlying mechanisms, and safety profile of CBD, and to discuss the challenges and future directions for its application in oncology.
A systematic review.
We integrated recent high-quality research to assess CBD's effects across various cancer types. The analysis encompassed its mechanisms in tumor cell biology and the tumor microenvironment (TME), a comparison of monotherapy versus combination therapy efficacy, its role in managing cancer-related symptoms, and its pharmacokinetic/pharmacodynamic properties. Advances in nano-based drug delivery systems were also reviewed.
CBD demonstrates multi-target anti-tumor effects, including inhibiting proliferation, inducing apoptosis, suppressing metastasis, and remodeling the TME via immunomodulation. It exhibits broad-spectrum efficacy in vitro and in vivo, shows synergistic effects in combination therapy, and can alleviate cancer-related symptoms. Safety data indicate a favorable tolerability profile. However, current evidence relies predominantly on preclinical models.
CBD holds substantial promise as an anti-tumor agent. This review provides a theoretical foundation for its rational development. Future work should focus on validating these findings in clinical trials, optimizing targeted drug delivery systems, and establishing standardized treatment protocols.
Authors
Duan Duan, Liu Liu, An An, Zhong Zhong, Guan Guan, Liu Liu, Zhang Zhang, Yang Yang
View on Pubmed